Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 5Breast Neoplasms 4Brain Neoplasms 3von Hippel-Lindau Disease 1Tonsillar Neoplasms 1Solid Tumor 1Sarcoma 1Prostatic Neoplasms 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Optic Nerve Diseases 1Neoplastic Cells, Circulating 1Hemangioblastoma 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Primary Liver Cancer 1

Interventions

gallium Ga 68 dotatate 1Magnetic Resonance Spectroscopy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × von Hippel-Lindau Disease × Bevacizumab × Clear all
NCT01015300 2012-05-11

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Dartmouth-Hitchcock Medical Center

Phase EARLY_PHASE1 Terminated
1 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡